{
  "id": "crs_grading",
  "title": "Cytokine Release Syndrome (CRS) Grading",
  "description": "Assesses severity of cytokine release syndrome in immunotherapy patients, particularly those receiving CAR-T cell therapy and other immune effector cell therapies. CRS is an acute inflammatory process marked by a spectrum of clinical symptoms and substantial elevations of serum cytokines.",
  "category": "oncology",
  "version": "ASTCT_2019",
  "parameters": [
    {
      "name": "fever_present",
      "type": "string",
      "required": true,
      "description": "Presence of fever (≥38°C) or fever suppressed by anti-pyretic/anti-cytokine therapy",
      "options": ["yes", "no"],
      "validation": {
        "enum": ["yes", "no"]
      }
    },
    {
      "name": "hypotension_status",
      "type": "string",
      "required": true,
      "description": "Hypotension status and intervention requirements",
      "options": [
        "none",
        "responsive_to_fluids",
        "low_dose_single_pressor",
        "high_dose_multiple_pressors"
      ],
      "validation": {
        "enum": [
          "none",
          "responsive_to_fluids", 
          "low_dose_single_pressor",
          "high_dose_multiple_pressors"
        ]
      }
    },
    {
      "name": "oxygen_requirement",
      "type": "string",
      "required": true,
      "description": "Oxygen support requirements",
      "options": [
        "none",
        "low_flow_oxygen",
        "high_flow_oxygen_40_plus",
        "ventilator_required"
      ],
      "validation": {
        "enum": [
          "none",
          "low_flow_oxygen",
          "high_flow_oxygen_40_plus", 
          "ventilator_required"
        ]
      }
    },
    {
      "name": "organ_toxicity_grade",
      "type": "integer",
      "required": true,
      "description": "Highest grade of organ toxicity (using CTCAE criteria, excluding fever and hypotension)",
      "validation": {
        "min": 0,
        "max": 4
      },
      "options": [
        {"value": 0, "label": "No organ toxicity", "description": "No evidence of organ dysfunction"},
        {"value": 1, "label": "Grade 1", "description": "Mild organ toxicity"},
        {"value": 2, "label": "Grade 2", "description": "Moderate organ toxicity"},
        {"value": 3, "label": "Grade 3", "description": "Severe organ toxicity"},
        {"value": 4, "label": "Grade 4", "description": "Life-threatening organ toxicity"}
      ]
    },
    {
      "name": "patient_age",
      "type": "integer",
      "required": false,
      "description": "Patient age in years (for risk stratification)",
      "validation": {
        "min": 0,
        "max": 120
      },
      "unit": "years"
    },
    {
      "name": "comorbidities_present",
      "type": "string",
      "required": false,
      "description": "Presence of significant comorbidities that may affect CRS management",
      "options": ["yes", "no", "unknown"],
      "validation": {
        "enum": ["yes", "no", "unknown"]
      }
    }
  ],
  "result": {
    "name": "crs_assessment",
    "type": "object",
    "unit": "grade",
    "description": "Comprehensive CRS grading with severity assessment and management recommendations"
  },
  "interpretation": {
    "ranges": [
      {
        "min": 1,
        "max": 1,
        "stage": "Grade 1 - Mild",
        "description": "Mild symptoms",
        "interpretation": "Symptoms not life-threatening; only symptomatic treatment required. Examples include fever, nausea, fatigue, headache, myalgias, malaise. Supportive care and symptomatic treatment indicated."
      },
      {
        "min": 2,
        "max": 2,
        "stage": "Grade 2 - Moderate",
        "description": "Moderate intervention required",
        "interpretation": "Moderate intervention required for response. Includes oxygen requirement <40%, hypotension responsive to fluids, low dose single pressor, or Grade 2 organ toxicity. Vigilant supportive care required."
      },
      {
        "min": 3,
        "max": 3,
        "stage": "Grade 3 - Severe",
        "description": "Aggressive intervention required",
        "interpretation": "Aggressive intervention required for response. Includes oxygen requirement ≥40%, hypotension requiring high-dose/multiple pressors, Grade 3 organ toxicity, or Grade 4 transaminitis. ICU management often required."
      },
      {
        "min": 4,
        "max": 4,
        "stage": "Grade 4 - Life-threatening",
        "description": "Life-threatening symptoms",
        "interpretation": "Life-threatening symptoms requiring immediate intensive intervention. Includes ventilator requirement or Grade 4 organ toxicity (excluding transaminitis). Intensive care management mandatory."
      },
      {
        "min": 5,
        "max": 5,
        "stage": "Grade 5 - Death",
        "description": "Death related to CRS",
        "interpretation": "Death directly attributable to cytokine release syndrome. Represents failure of all therapeutic interventions."
      }
    ]
  },
  "clinical_applications": [
    "CAR-T cell therapy monitoring",
    "Immune effector cell therapy complications",
    "Immunotherapy toxicity assessment",
    "ICU triage and management decisions",
    "Clinical trial endpoint assessment",
    "Treatment response monitoring",
    "Risk stratification for intervention"
  ],
  "treatment_recommendations": {
    "grade_1": [
      "Supportive care with symptomatic treatment",
      "Monitor vital signs and symptoms",
      "Adequate hydration and fever management",
      "No specific anti-cytokine therapy required"
    ],
    "grade_2": [
      "Vigilant supportive care with close monitoring",
      "Consider tocilizumab if extensive comorbidities present",
      "Fluid management and low-dose vasopressors if needed",
      "Monitor for progression to higher grades"
    ],
    "grade_3": [
      "Aggressive supportive care, often requiring ICU",
      "Tocilizumab ± corticosteroids recommended",
      "High-dose or multiple vasopressors as needed",
      "Consider corticosteroids if no improvement at 24 hours"
    ],
    "grade_4": [
      "Intensive care management mandatory",
      "Immediate tocilizumab and corticosteroids",
      "Mechanical ventilation and advanced organ support",
      "Multidisciplinary critical care approach"
    ]
  },
  "references": [
    "Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758.",
    "Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35. doi: 10.1186/s13045-018-0571-y.",
    "Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47-62. doi: 10.1038/nrclinonc.2017.148.",
    "Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J. 2014;20(2):119-122. doi: 10.1097/PPO.0000000000000035."
  ],
  "formula": "CRS Grade determined by highest severity parameter: fever requirement + maximum of (hypotension grade, oxygen requirement grade, organ toxicity grade)",
  "notes": [
    "Based on ASTCT (American Society for Transplantation and Cellular Therapy) consensus criteria",
    "Fever ≥38°C required for Grade 1; not required for Grades 2-4 if anti-pyretic/anti-cytokine therapy given",
    "Hypotension should be defined case-by-case considering patient's age and baseline",
    "Organ toxicity graded using Common Terminology Criteria for Adverse Events (CTCAE)",
    "Grade 4 transaminitis (liver toxicity) is considered Grade 3 CRS, not Grade 4",
    "Requires specialized clinical expertise and frequent monitoring",
    "Treatment should be individualized based on patient comorbidities and clinical status",
    "Early recognition and prompt intervention are critical for optimal outcomes",
    "Monitor for infection as immunosuppressive treatments may increase infection risk"
  ],
  "validation": {
    "population": "Patients receiving immune effector cell therapies (CAR-T, TCR-T, etc.)",
    "settings": ["Oncology units", "ICU", "Bone marrow transplant units", "Clinical trials"],
    "consensus_basis": "ASTCT expert consensus 2019",
    "clinical_utility": "Standardizes CRS assessment across institutions and clinical trials"
  }
}